Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Waleed El-Feky

Neurology Dallas, TX Medical Doctor

NPI 1528033362 CMS profile 295852

6080 N Central Expy Ste 100, Dallas, TX 75206

Open in the dashboard

General payments

$586,553

1,394 records reported · program years 2019–2025

Research payments

$2,975

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$1,132,912

7 holdings reported · through program year 2025

Research they led as principal investigator

$791,511 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Waleed El-Feky of Dallas, TX is reported in the CMS Open Payments database as having received $586,553 across 1,394 general payments and $2,975 in research payments paid to them. Separately, studies naming them as principal investigator received $791,511 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $1,132,912 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

15 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $164,058 225
2024 General $201,246 336
2023 General $93,556 243
2022 General $89,819 229
2021 General $17,550 157
2020 General $9,184 86
2019 General $11,140 118
2019 Research $2,975 1
2025 Ownership $468,226 1
2024 Ownership $292,578 1
2023 Ownership $172,611 1
2022 Ownership $110,633 1
2021 Ownership $51,484 1
2020 Ownership $27,874 1
2019 Ownership $9,505 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Waleed El-Feky
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Waleed El-Feky were reported at $164,058. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Waleed El-Feky Neurology median Middle half National median
2019 $11,140 $474 $118–$2,177 $163
2020 $9,184 $367 $82–$2,309 $114
2021 $17,550 $438 $104–$2,547 $132
2022 $89,819 $442 $103–$2,388 $149
2023 $93,556 $464 $119–$2,312 $160
2024 $201,246 $468 $119–$2,323 $164
2025 $164,058 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Averitas Pharma Inc. $113,923 209 payments
  2. Lilly USA, LLC $104,979 139 payments
  3. Ipsen Biopharmaceuticals, Inc $73,738 48 payments
  4. Biogen, Inc. $53,950 63 payments
  5. GRT US Holding, Inc. $53,271 89 payments
  6. Amgen Inc. $37,590 37 payments
  7. Axsome Therapeutics, Inc. $37,207 40 payments
  8. Allergan Inc. $30,236 70 payments
  9. E.R. Squibb & Sons, L.L.C. $16,682 13 payments
  10. TG Therapeutics, Inc. $15,896 20 payments
  11. Other $49,082 666 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $319,088 136 payments
  2. Honoraria $145,003 78 payments
  3. Travel and Lodging $56,057 234 payments
  4. Consulting Fee $38,660 17 payments
  5. Food and Beverage $25,527 923 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $1,875 1 payment
  7. Education $343 5 payments
Products named General payments · program years 2019–2025
  1. Qutenza $167,194 298 payments
  2. KISUNLA $107,144 104 payments
  3. DYSPORT $73,738 48 payments
  4. Sunosi $37,201 39 payments
  5. VUMERITY $32,744 32 payments
  6. UPLIZNA $29,154 30 payments
  7. BOTOX $28,585 47 payments
  8. BRIUMVI $15,896 20 payments
  9. ZEPOSIA $14,855 39 payments
  10. TYSABRI $11,186 29 payments
  11. Other $44,844 773 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $2,975 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

994

Median for Neurology: 833

Drug cost

$528,662

Median for Neurology: $202,670

Branded share of claims

30.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 36 $175,962
Zeposia Ozanimod Hydrochloride Brand 11 $117,169
Austedo Deutetrabenazine Brand 13 $105,106
Inbrija Levodopa Brand 13 $76,335
Rytary Carbidopa/Levodopa Brand 21 $38,894
Memantine Hcl Generic 155 $3,256
Carbidopa-Levodopa Carbidopa/Levodopa Brand 116 $2,571
Gabapentin Generic 113 $1,489
Butalbital-Aspirin-Caffeine Butalbital/Aspirin/Caffeine Brand 13 $1,077
Doxepin Hcl Generic 43 $748

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$424,493

Of which drugs: $210,027

Medicare patients

651

Average age 74

Services billed

144,798

343 women, 308 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 33%
Depression 32%
Diabetes 30%
Chronic kidney disease 23%
Alzheimer's or dementia 19%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Capsaicin 8% patch, per square centimeter J7336 Office 14 20,720 $53,679
Injection, gadoterate meglumine, 0.1 ml A9575 Office 123 20,140 $1,873

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
$75,771 — 20,720
DYSPORT
$38,760 — —
KISUNLA
$19,384 — —
ZEPOSIA
$10,626 11 —
TYSABRI
$6,441 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

1,395 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record